The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 20, 2019
Filed:
Apr. 27, 2017
Applicant:
Ultimovacs As, Oslo, NO;
Inventors:
Assignee:
ULTIMOVACS AS, Oslo, NO;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); C07K 7/08 (2006.01); C12N 9/12 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/435 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); C12N 9/1276 (2013.01); C12Y 207/07049 (2013.01); A61K 38/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/53 (2013.01);
Abstract
A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.